

Title (en)
ABLATIVE IMMUNOTHERAPY

Title (de)
ABLATIVE IMMUNOTHERAPIE

Title (fr)
IMMUNOTHÉRAPIE ABLATIVE

Publication
EP 2970910 A4 20161116 (EN)

Application
EP 14779681 A 20140310

Priority
• US 201313796171 A 20130312
• US 2014022287 W 20140310

Abstract (en)
[origin: WO2014164396A1] The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Th1 cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.

IPC 8 full level
C12N 5/0783 (2010.01); **A61K 35/26** (2006.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP IL)
A61K 35/26 (2013.01 - EP IL); **A61K 39/39** (2013.01 - CN IL); **A61K 39/4611** (2023.05 - CN EP IL); **A61K 39/464499** (2023.05 - CN EP IL); **A61P 31/00** (2018.01 - EP IL); **A61P 31/10** (2018.01 - EP IL); **A61P 31/12** (2018.01 - EP IL); **A61P 35/00** (2018.01 - EP IL); **C12N 5/0636** (2013.01 - CN EP IL); **A61K 2039/55588** (2013.01 - CN IL); **A61K 2039/57** (2013.01 - CN IL); **A61K 2239/26** (2023.05 - CN EP IL); **A61K 2239/31** (2023.05 - CN EP IL); **A61K 2239/38** (2023.05 - CN EP IL); **Y02A 50/30** (2018.01 - EP)

C-Set (source: CN EP IL)
CN IL

A61K 39/464499 + A61K 2300/00
EP
1. **A61K 35/26 + A61K 2300/00**
2. **A61K 39/464499 + A61K 2300/00**

Citation (search report)
• [I] US 6277368 B1 20010821 - HISERODT JOHN C [US], et al
• [A] GERHARD A. MÜLLER ET AL: "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", NATURE MEDICINE., vol. 6, no. 3, 1 March 2000 (2000-03-01), US, pages 332 - 336, XP055308901, ISSN: 1078-8956, DOI: 10.1038/73193
• See also references of WO 2014164396A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2014164396 A1 20141009; AU 2014249374 A1 20150924; AU 2020201309 A1 20200312; BR 112015022974 A2 20170718; BR 112015022974 A8 20191126; CA 2904853 A1 20141009; CN 105102613 A 20151125; CN 106581673 A 20170426; EP 2970910 A1 20160120; EP 2970910 A4 20161116; IL 241326 A0 20151130; IL 241326 B 20210531; JP 2016518319 A 20160623; JP 6538647 B2 20190703; KR 102265276 B1 20210616; KR 20150138234 A 20151209; PH 12015502086 A1 20160118; SG 10201707446P A 20171030; SG 11201507350W A 20151029

DOCDB simple family (application)
US 2014022287 W 20140310; AU 2014249374 A 20140310; AU 2020201309 A 20200221; BR 112015022974 A 20140310; CA 2904853 A 20140310; CN 201480014494 A 20140310; CN 201710016168 A 20140310; EP 14779681 A 20140310; IL 24132615 A 20150908; JP 2016500938 A 20140310; KR 20157028277 A 20140310; PH 12015502086 A 20150911; SG 10201707446P A 20140310; SG 11201507350W A 20140310